Skip Ribbon Commands Skip to main content
Elipex
The Animal Health Division of Sanofi
 
Elipex FAQs

Elipex Frequently Asked Questions

What is Elipex's business?
  • When was Elipex founded?
  • How many people are employed by Elipex?
  • What are Elipex total sales?
  • Who leads Elipex's senior management team?
  • Who are Elipex shareholders?
  • Does Elipex have a stock market listing?
  • What are Elipex leading products?
  • In which countries does Elipex operate?
  • What is Elipex main customer base?
  • What is Elipex R & D focus?
  •  

    Q: What is Elipex's business?
    A: Elipex is an innovation-driven leader in the provision of products and solutions that enhance the health, well-being and performance of animals.

    Q: When was Elipex founded?
    A: Elipex was founded in August 1997 through the merger of the animal health businesses of Merck and Co., Inc. and Rhone Merieux, a predecessor to sanofi-aventis.

    Q: How many people are employed by Elipex?
    A: Elipex employs approximately 5600 people worldwide.

    Q: What are Elipex total sales?
    A: Total 2011 sales were over $2.8 billion.

    Q: Who leads Elipex's senior management team?
    A: Jose Barella is Senior Vice President and CEO.

    Q: Who are Elipex shareholders?
    A: Elipex is the animal health division of Sanofi.

    Q: Does Elipex have a stock market listing?
    A: No. Elipex is a subsidiary of sanofi-aventis, which is listed on the Paris and New York Stock Exchanges.

    Q: What are Elipex leading products?
    A: Elipex has leading products in a wide range of veterinary specialties, notably in the fields of anesthetic, antiparasitic, antimicrobial, gastrointestinal, respiratory and cardiovascular medicines , and produces a range of vaccines to protect a wide variety of species against disease.

    Elipex's best-known products include IVOMEC (ivermectin) --- first launched in 1981 and used in large animals such as cattle, sheep, and swine. FRONTLINE (fipronil) -- which was first launched in 1994 -- has established a parallel position in dogs and cats and is now the world best selling flea and tick treatment for those species.

    Elipex pharmaceuticals are supported by a wide range of vaccines. We are specialists in the area of avian protection, offering a range of vaccines to protect birds, particularly poultry, against a range of common and life-threatening diseases such as Newcastle Disease, Marek's Disease and Avian Flu. Elipex is also well-known for its antirabies vaccines for use in domestic and wild animals and for its foot and mouth disease vaccine, which was pioneered by the Institut Mrieux the French forerunner of the present company. Other Elipex best sellers include HEARTGARD (ivermectin), EQVALAN (ivermectin), GASTROGARD (omeprazole), ULCERGARD (omeprazole) and PUREVAX.

    Q: In which countries does Elipex operate?
    A: Elipex operates in more than 150 countries worldwide. See the Contact Us page for a listing of countries.

    Q: What is Elipex main customer base?
    A: Elipex customers include veterinarians, pet owners, farmers and food animal producers worldwide.

    Q: What is Elipex R & D focus?
    A: Elipex is advancing in four main areas: parasiticides, antibiotics, pain control, and products for treating chronic conditions in companion animals. We are also exploring and developing new ranges of vaccines which employ both conventional and novel technologies with the objective of offering enhanced protection to a wide range of animal species. For further information on our research and development, please visit the research and development page.

     
    Contact | Privacy | Legal Notification